Tango Therapeutics (TNGX) AI Stock Analysis

• Market Cap: $772.15M
• Dividend Yield: N/A
• Average Volume (3M): 1.70M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: -42.84%
• EPS Growth: -17.32%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 111,260,250
• 10 Day Avg. Volume: 1,353,525
• 30 Day Avg. Volume: 1,704,335
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: 17.28
• Enterprise Value/Gross Profit: 17.73
• Enterprise Value/Ebitda: -2.75
• 1Y Price Target: $11.00
• Price Target Upside: 61.53% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 47 Neutral
• Price Target: $7.00 ▲(2.79% Upside)

Tango Therapeutics' overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. While technical indicators show some positive momentum, the negative valuation metrics and recent executive resignation add to the uncertainty. The company needs to address its financial and operational challenges to improve its stock attractiveness.

Positive Factors

Analyst Ratings

Analysts have reiterated a Buy rating for Tango Therapeutics, Inc.'s stock.

Clinical Trials

The combination of TNG462 and Revolution Medicines' inhibitors has shown enhanced antitumor activity compared to using either compound alone.

Earnings

Tango ended the quarter with $180.8 million in cash and marketable securities, providing an operational runway into the first quarter of 2027.

Negative Factors

Clinical Risks

Risks include negative clinical results with the lead asset, TNG462, and delays in advancing pipeline candidates into registrational trials.

Competition

Competitive risks exist, especially with respect to other clinical-stage PRMT5 inhibitors.

Tango Therapeutics Business Overview & Revenue Model

Company Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Tango Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies. These partnerships often involve licensing agreements, where Tango provides access to its proprietary technology or drug candidates in exchange for upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future product sales. Additionally, Tango may receive funding from research grants and government contracts to support its R&D activities, contributing to its revenue streams.

Tango Therapeutics Financial Statement Overview

Summary

Tango Therapeutics faces substantial financial challenges, characterized by declining revenue and consistent operational losses. The strong gross profit margin of 98.46% is overshadowed by a deeply negative net profit margin of -322.71% and negative cash flows. The company's reliance on equity financing is notable but does not offset its inefficiencies in generating returns and managing cash flows.

Income Statement

Tango Therapeutics shows declining revenue with a recent drop from $42.1M to $40.99M (TTM). The company has consistently operated at a loss, with negative EBIT and net profit margins. The gross profit margin is strong at 98.46%, but the net profit margin is deeply negative at -322.71%, indicating significant operational challenges.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.22, reflecting cautious leverage. Return on Equity is poor at -79.32%, showing inefficiencies in generating returns from equity. The equity ratio of 60.79% indicates a strong reliance on equity financing.

Cash Flow

Tango Therapeutics struggles with cash flows, as highlighted by the negative free cash flow growth rate. The operating cash flow to net income ratio is slightly negative, indicating cash outflows exceed net income. The company needs to improve its operational cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	24.30M	42.07M	36.53M	24.86M	37.04M	7.66M
Gross Profit	23.67M	42.07M	-78.67M	20.83M	35.08M	6.03M
EBITDA	-152.65M	-143.10M	-111.76M	-109.46M	-57.29M	-51.48M
Net Income	-145.57M	-130.30M	-101.74M	-108.18M	-58.23M	-51.86M
Balance Sheet
Total Assets	237.89M	316.49M	402.57M	436.47M	500.15M	207.25M
Cash, Cash Equivalents and Short-Term Investments	181.21M	257.92M	336.88M	366.13M	485.25M	190.32M
Total Debt	35.01M	36.49M	38.92M	41.13M	1.50M	7.88M
Total Liabilities	102.94M	116.97M	149.46M	186.99M	155.41M	168.65M
Stockholders Equity	134.95M	199.52M	253.11M	249.48M	344.75M	38.60M
Cash Flow
Free Cash Flow	-149.17M	-132.25M	-119.51M	-116.77M	-61.36M	68.97M
Operating Cash Flow	-148.25M	-131.50M	-117.98M	-109.08M	-59.53M	70.07M
Investing Cash Flow	132.00M	86.13M	41.43M	26.40M	-183.43M	-145.47M
Financing Cash Flow	3.95M	47.66M	82.41M	1.61M	357.32M	80.88M

Tango Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Positive. The current price of 6.81 is below the 20-day moving average (MA) of 6.84, above the 50-day MA of 6.51, and above the 200-day MA of 3.59, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 53.72 is Neutral, neither overbought nor oversold. The STOCH value of 51.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNGX.

Tango Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FULC	56 Neutral	$414.34M	―	-30.00%	―	-100.00%	-266.37%
RZLT	53 Neutral	$695.97M	―	-95.15%	―	―	-1.69%
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
ACIU	51 Neutral	$225.59M	―	-50.57%	―	91.44%	18.94%
TNGX	47 Neutral	$772.15M	―	-76.09%	―	-42.84%	-17.32%
IKT	46 Neutral	$124.44M	―	-97.49%	―	-100.00%	62.82%
DMAC	42 Neutral	$317.37M	―	-73.41%	―	―	-31.78%

Tango Therapeutics Corporate Events

Tango Therapeutics’ Chief Legal Officer Resigns

On August 21, 2025, Douglas Barry announced his resignation as Chief Legal and Compliance Officer and Corporate Secretary of Tango Therapeutics, effective September 12, 2025, to pursue another opportunity. This change in leadership may impact Tango Therapeutics’ operations and strategic direction as they adjust to the departure of a key executive.

Tango Therapeutics Approves Key Proposals at Annual Meeting

On June 5, 2025, Tango Therapeutics held its annual stockholders meeting where several key proposals were approved. Notably, the amendment to increase authorized common stock shares from 200 million to 400 million was passed, potentially enhancing the company’s capital structure and flexibility. Additionally, Lesley Ann Calhoun was elected as a Class I director, and PricewaterhouseCoopers, LLP was ratified as the independent accounting firm for the fiscal year ending December 31, 2025. The stockholders also approved executive compensation policies and decided on an annual frequency for future advisory votes on executive compensation.